ADRI (Alzheimer's Disease Risk Index)
Power-Stem's patented inspection technology utilizes advanced Enzyme-Linked Immunosorbent Assay (ELISA) tools to accurately measure the concentration of oxidative proteins disorder (GAPDH) associated with neuronal decay, providing a precise assessment of the risk for Alzheimer's disease.
With a clinical accuracy rate of 95.74% and high sensitivity in detecting this chronic neurological disorder, the ADRI inspection patent has received global patent authorization, being a trailblazer in Alzheimer's disease analysis.
![Beauty-Stem Biomedical_Taiwan Patent](images/certificate_220220920121228.jpg)
Taiwan Patent
![Beauty-Stem Biomedical_Japan Patent](images/certificate_320220920121231.jpg)
Japan Patent
![Beauty-Stem Biomedical_China Patent](images/certificate_420220920122412.jpg)
China Patent
![Beauty-Stem Biomedical_US Patent](images/certificate_520220920121231.png)
US Patent
![Beauty-Stem Biomedical_EU Patent](images/certificate_620220920121233.jpg)